NDA 208623 · Amicus Therap US
Galafold
Migalastat Hydrochloride · Oral
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 10, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
28
12 Phase 3, 4 recruiting
FAERS reports
558
440 serious, 77 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 28, 2025.
GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ( GLA ) variant based on in vitro assay data [see Dosage and Administration (2.1) and Clinical Pharmacology (12.1) ] . This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. GALAFOLD is an alpha-galactosidase A (alpha-Gal A) pharmacological chaperone indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ( GLA ) variant based on in vitro assay data. ( 1 , 12.1 ) This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. ( 1 )
Mechanism: Migalastat is a pharmacological chaperone that reversibly binds to the active site of the alpha-galactosidase A (alpha-Gal A) protein (encoded by the galactosidase alpha gene, GLA ), which is deficient in Fabry disease. This binding stabilizes alpha-Gal A allowing its trafficking from the endoplasmic reticulum into the lysosome where it exerts its action. In the lysosome, at a lower pH and at a higher concentration of relevant substrates, migalastat dissociates from alpha-Gal A allowing it to break down the glycosphingolipids globotriaosylceramide (GL-3) and globotriaosylsphingosine (lyso-Gb...
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 10, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
- GALAFOLD · MIGALASTAT HYDROCHLORIDE EQ 123MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Migalastat" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry DiseasePivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT03425539 · 118 participants · Start Jun 21, 2018 · Primary completion Aug 17, 2021
Drug: Lucerastat; Placebo · For: Fabry Disease
Sites: Birmingham, Alabama; Irvine, California; Oakland, California · 49 sites in all
- A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseasePivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT03737214 · 107 participants · Start Dec 18, 2018 · Primary completion Aug 31, 2026
Drug: Lucerastat · For: Fabry Disease
Sites: Birmingham, Alabama; Irvine, California; Oakland, California · 42 sites in all
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseasePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05280548 · 104 participants · Start May 3, 2022 · Primary completion May 22, 2026
Drug: Venglustat (GZ402671); Agalsidase alfa and 2 more · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Atlanta, Georgia · 54 sites in all
- Open-Label Phase 3 Long-Term Safety Study of MigalastatPivotal-lookingTerminated
Amicus TherapeuticsIndustry
NCT01458119 · 85 participants · Start Oct 14, 2011 · Primary completion Feb 17, 2016
Drug: migalastat hydrochloride · For: Fabry Disease
Sites: Atlanta, Georgia; Chicago, Illinois; Kansas City, Kansas · 25 sites in all
- Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT02194985 · 84 participants · Start Mar 14, 2015 · Primary completion Oct 23, 2019
Drug: migalastat HCl 150 mg · For: Fabry Disease
Sites: Atlanta, Georgia; Kansas City, Kansas; Grand Rapids, Michigan · 28 sites in all
- Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT01218659 · 68 participants · Start Sep 8, 2011 · Primary completion May 27, 2014
Drug: migalastat hydrochloride; agalsidase · For: Fabry Disease
Sites: Los Angeles, California; Aurora, Colorado; Decatur, Georgia · 25 sites in all
- Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT00925301 · 67 participants · Start Oct 23, 2009 · Primary completion Jun 12, 2012
Drug: migalastat hydrochloride; Placebo · For: Fabry Disease
Sites: Los Angeles, California; San Francisco, California; Decatur, Georgia · 28 sites in all
Idorsia Pharmaceuticals Ltd.Industry
NCT03832452 · 44 participants · Start Feb 14, 2019 · Primary completion Apr 22, 2019
Drug: Lucerastat (Treatment A); Moxifloxacin and 2 more · For: Healthy
Sites: Groningen, Netherlands
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue43
- renal impairment42
- death35
- off label use34
- cerebrovascular accident27
- fatigue27
- headache27
- nausea24
- pain23
- dyspnoea22
- drug ineffective21
- inappropriate schedule of product administration20
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 14 |
| 2019 | 58 |
| 2020 | 93 |
| 2021 | 55 |
| 2022 | 49 |
| 2023 | 49 |
| 2024 | 109 |
| 2025 | 91 |
| 2026 | 40 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Galafold (Migalastat HCl)
2024 spending
$46.5M
Beneficiaries
148
1,436 claims
Per beneficiary
$314,001
$2,205.60 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $16,524,295 |
| 2021 | $22,136,474 |
| 2022 | $26,798,625 |
| 2023 | $34,842,425 |
| 2024 | $46,472,090 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Hughes DA, Nicholls K, Shankar SP, et al. · J Med Genet 2017 · Clinical Trial, Phase III, Randomized Controlled Trial
- Long-term efficacy of migalastat in females with Fabry disease.
Kallish S, Camporeale A, Hopkin RJ, et al. · J Med Genet 2025 · Clinical Trial, Phase III, Multicenter Study
- A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry's Disease.
Majid H, Verma N, Bhandari S, et al. · Expert Opin Pharmacother 2024 · Systematic Review
- Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
Germain DP, Hughes DA, Nicholls K, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Randomized Controlled Trial
- Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
Hughes DA, Nicholls K, Sunder-Plassmann G, et al. · Am J Med Genet A 2019 · Clinical Trial, Phase III, Letter
- Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension.
Ramaswami U, Font-Montgomery E, Goker-Alpan O, et al. · Mol Genet Metab 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Amicus Therap US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.